Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5624 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates 2019-01-07
Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation 2019-01-04
Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform 2019-01-04
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield Management: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners 2019-01-04
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures 2019-01-04
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services 2019-01-03
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency 2019-01-01
Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 2019-01-01
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered FIA-MRMS system 2018-12-31
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered impact-II UHR-QTOF LC-MS/MS system 2018-12-31
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered timsTOF Pro LC/CCS/MS/MS system 2018-12-31
Murdoch Univ–Bruker Corp: NMR spectrometer, 2018 supply ordered Avance IVDr 600 NMR system 2018-12-31
Harpoon Therapeutics–SEVERAL: investment, 201812– IPO $86m FILED 2018-12-27
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Annexon Biosciences–SEVERAL: investment, 201812 financing round Series C $75m led by new investor Bain Capital Life Sciences 2018-12-19
Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb 2018-12-18
PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
Seer–Invus Group: investment, –201812 financing rounds Series A + B totalling $36m incl Series B lead investor Invus 2018-12-17
Seer–Maverick Ventures: investment, –201812 financing rounds Series A + B totalling $36m incl Series A lead investor Maverick Ventures 2018-12-17
Seer–SEVERAL: investment, –201812 financing rounds Series A + B of $36m until 12/18 as company emerges from stealth 2018-12-17
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech 2018-12-13
Mestrelab Research–Bruker Corp: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH 2018-12-10
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare 2018-12-10
Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB 2018-12-06
Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development 2018-12-06
Novartis–Qiagen: molecular companion diagnostics, 201812– collab developm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG 2018-12-05
Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA 2018-12-05
Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA 2018-12-05
CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG 2018-12-05
Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG 2018-12-05
Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH 2018-12-05
Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH 2018-12-05
Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH 2018-12-05
Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Argenx–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argenx: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology 2018-11-28
Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures 2018-11-27
SpinDiag–SEVERAL: investment, 201811 financing round Series A €3m 2018-11-27
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development 2018-11-26
Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE 2018-11-26
F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d 2018-11-22
Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases 2018-11-21
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners 2018-11-19
Inflazome–Fountain Healthcare Partners: investment, 201811 financing round Series B totalling €40m incl existing + co-investor FHP 2018-11-19
Inflazome–Longitude Capital: investment, 201811 financing round Series B totalling €40m incl new + co-investor Longitude Capital 2018-11-19
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners 2018-11-19
next pagenext page 1 2 3 4 ... 55 56 57  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top